MONTRÉAL, QC / ACCESS Newswire / November 6, 2025 / Valsoft Corporation Inc. ("Valsoft"), a Canadian company specializing in the acquisition and development of vertical market software businesses, ...

Rootstock Software, a leading provider of cloud ERP for product companies, today announced the establishment of Rootstock Software India Private Limited (Rootstock India), a wholly owned subsidiary ...

Q3 2025 Management View CEO Ramy Farid reported "very solid progress during the third quarter," highlighting total revenue of $54 million, a 54% increase from the third quarter of 2024. Software ...

PainReform Ltd. (Nasdaq: PRFX), today announced that DeepSolar, its solar energy business unit developing next-generation AI-driven solar analytics, was recently featured in a Watchlist Interview ...

Whether you're recruiting new talent or looking to make payroll more efficient, these companies can help reach your goals.

Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix® ), a life sciences innovator, manufacturer, and exporter, ...

CFO and COO Mark Hirschhorn reported, "in the third quarter, we delivered results ahead of expectations for both revenue and adjusted EBITDA, reflecting stronger subscription retention, increased ...

Companies this past month announced many new products and services that use artificial intelligence to automate complex processes, secure data and improve care coordination and interoperability ...

Copenhagen, Denmark, November 4, 2025, (GLOBE NEWSWIRE) – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR), today announced an update on its ongoing adult clinical study in the US.

Mechelen, Belgium; November 3, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present new and updated data for CAR T-cell therapy candidate, GLPG51011, at the ...

High-paying remote finance director jobs often involve managing accounting and financial control functions, establishing ...

Preliminary results confirm earlier findings that inobrodib in combination with pomalidomide + dexamethasone (InoPd) for multiple myeloma has promising clinical activity and a tolerable safety profile ...